A robust, good manufacturing practice-compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy.

[1]  Jeffrey A. Bluestone,et al.  Type 1 diabetes immunotherapy using polyclonal regulatory T cells , 2015, Science Translational Medicine.

[2]  V. Kuchroo,et al.  TIGIT predominantly regulates the immune response via regulatory T cells. , 2015, The Journal of clinical investigation.

[3]  Wei Zhang,et al.  An innovative method to generate a Good Manufacturing Practice-ready regulatory T-cell product from non-mobilized leukapheresis donors. , 2015, Cytotherapy.

[4]  O. Rotzschke,et al.  Large-scale Isolation of Highly Pure “Untouched” Regulatory T Cells in a GMP Environment for Adoptive Cell Therapy , 2015, Journal of immunotherapy.

[5]  W. Młynarski,et al.  Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up. , 2014, Clinical immunology.

[6]  M. Battaglia,et al.  Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors , 2014, Leukemia.

[7]  Helen E. Heslop,et al.  Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease , 2013, Haematologica.

[8]  S. Appel,et al.  Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms , 2012, Neurobiology of Disease.

[9]  S. Powell,et al.  Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival , 2012, EMBO molecular medicine.

[10]  Herman Waldmann,et al.  Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. , 2012, Immunity.

[11]  M. Battaglia,et al.  Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells , 2011, Haematologica.

[12]  R. Negrin,et al.  Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. , 2011, Blood.

[13]  Bruce R. Blazar,et al.  Massive ex Vivo Expansion of Human Natural Regulatory T Cells (Tregs) with Minimal Loss of in Vivo Functional Activity , 2011, Science Translational Medicine.

[14]  R. Lechler,et al.  Human Regulatory T Cells with Alloantigen Specificity Are More Potent Inhibitors of Alloimmune Skin Graft Damage than Polyclonal Regulatory T Cells , 2011, Science Translational Medicine.

[15]  B. Falini,et al.  Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. , 2011, Blood.

[16]  P. Worley,et al.  The mammalian Target of Rapamycin (mTOR) regulates T helper cell differentiation through the selective activation of mTORC1 and mTORC2 signaling , 2011, Nature Immunology.

[17]  Mario Roederer,et al.  Interpretation of cellular proliferation data: Avoid the panglossian , 2011, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[18]  J. Wagner,et al.  Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. , 2011, Blood.

[19]  M. Munson.  An improved technique for calculating relative response in cellular proliferation experiments , 2010, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[20]  T. Issekutz,et al.  CXCR3 blockade inhibits T‐cell migration into the CNS during EAE and prevents development of adoptively transferred, but not actively induced, disease , 2010, European journal of immunology.

[21]  C. Weston,et al.  Distinct Roles for CCR4 and CXCR3 in the Recruitment and Positioning of Regulatory T Cells in the Inflamed Human Liver , 2010, The Journal of Immunology.

[22]  P. Worley,et al.  The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. , 2009, Immunity.

[23]  A. Thomson,et al.  Immunoregulatory functions of mTOR inhibition , 2009, Nature Reviews Immunology.

[24]  I. Joosten,et al.  Clinical Grade Treg: GMP Isolation, Improvement of Purity by CD127pos Depletion, Treg Expansion, and Treg Cryopreservation , 2008, PloS one.

[25]  E. Bonifacio,et al.  Rapamycin Monotherapy in Patients With Type 1 Diabetes Modifies CD4+CD25+FOXP3+ Regulatory T-Cells , 2008, Diabetes.

[26]  T. Miyazaki,et al.  Therapeutic effect of CXCR3-expressing regulatory T cells on liver, lung and intestinal damages in a murine acute GVHD model , 2008, Gene Therapy.

[27]  P. Rossini,et al.  Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. , 2007, Blood.

[28]  R. Lechler,et al.  In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. , 2007, Blood.

[29]  R. Andreesen,et al.  Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. , 2006, Blood.

[30]  M. Battaglia,et al.  Rapamycin Promotes Expansion of Functional CD4+CD25+FOXP3+ Regulatory T Cells of Both Healthy Subjects and Type 1 Diabetic Patients1 , 2006, The Journal of Immunology.

[31]  E. Shevach.  From vanilla to 28 flavors: multiple varieties of T regulatory cells. , 2006, Immunity.

[32]  D. Valmori,et al.  Rapamycin-Mediated Enrichment of T Cells with Regulatory Activity in Stimulated CD4+ T Cell Cultures Is Not Due to the Selective Expansion of Naturally Occurring Regulatory T Cells but to the Induction of Regulatory Functions in Conventional CD4+ T Cells1 , 2006, The Journal of Immunology.

[33]  Lan Guo,et al.  Development of rabbit monoclonal and polyclonal antibodies for detection of site-specific histone modifications and their application in analyzing overall modification levels , 2006, Cell Research.

[34]  W. Zou.  Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[35]  E. Holler,et al.  Isolation of CD4+CD25+ regulatory T cells for clinical trials. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[36]  M. Battaglia,et al.  Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. , 2005, Blood.

[37]  Matthias Edinger,et al.  Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. , 2005, Blood.

[38]  Wei Zhang,et al.  Transplantation tolerance mediated by regulatory T cells in mice. , 2004, Chinese medical journal.

[39]  R. Steinman,et al.  CD25+ CD4+ T Cells, Expanded with Dendritic Cells Presenting a Single Autoantigenic Peptide, Suppress Autoimmune Diabetes , 2004, The Journal of experimental medicine.

[40]  Clare Baecher-Allan,et al.  Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis , 2004, The Journal of experimental medicine.

[41]  C. Fathman,et al.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.

[42]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[43]  C. Baecher-Allan,et al.  Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis , 2003, European journal of immunology.

[44]  Fiona Powrie,et al.  Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation , 2000, The Journal of experimental medicine.

[45]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[46]  M. Peakman,et al.  Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. , 2005, Diabetes.

[47]  Ray H. Baughman,et al.  Supporting Online Material , 2003 .